ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Chris Harris from Enanta Pharmaceuticals presented…
Infectious Diseases
-
-
ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV
Herpes simplex viruses (HSV) are common infections caused mainly by HSV-1 (usually oral) and HSV-2 (usually genital), although either type…
-
RFK Jr faces legal challenge from 15 US states over childhood vaccine recommendations
More than a dozen US states have sued the Trump administration in a bid to reverse recent changes to childhood…
-
WHO wants improved universal vaccines to win global influenza battle
The World Health Organization (WHO) has outlined the benefits that improved influenza vaccines could offer, as the agency seeks to…
-
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its…
-
JPM26: Enanta outlines strategy to lead in RSV therapeutics
At the 44th Annual J.P. Morgan Healthcare Conference, Enanta Pharmaceuticals discussed its respiratory syncytial virus (RSV) portfolio and the need…
-
JPM26: HIV pipeline dosing optionality gives Gilead advantage
Gilead’s range of treatments and prevention for human immunodeficiency virus (HIV), both on the market and in the pipeline, provides…
-
GSK to file for approval of hep B drug on positive Phase III data
GSK’s triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis B…
-
Sanofi buys hep B vaccine maker for $2.2bn
Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's…
-
UK approves Gilead’s twice-yearly HIV PrEP drug
Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering…
